# OnCo record immune-surveillance-immunoediting (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/immune-surveillance-immunoediting/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "immune-surveillance-immunoediting" ;
  schema:name "Immune surveillance and cancer immunoediting"@en ;
  schema:alternateName "immunosurveillance"@en, "immune surveillance hypothesis"@en, "cancer immunoediting"@en, "three Es"@en, "elimination equilibrium escape"@en, "Burnet-Thomas hypothesis"@en ;
  schema:description "The immune system patrols for cells that have turned malignant and destroys most of them; the tumours we see are the ones that learned to hide. Ehrlich guessed this in 1909, Burnet and Thomas argued it in the 1950s, it was declared dead in the 1970s, and Robert Schreiber's mouse experiments revived it in 2001. Checkpoint inhibitors, which can cure some metastatic melanoma, are its vindication."@en ;
  schema:url <https://onco.cc/terms/immune-surveillance-immunoediting/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cancer_immunoediting> ;
  schema:citation <https://doi.org/10.1136/bmj.1.5022.779>, <https://doi.org/10.1159/000386035>, <https://doi.org/10.1126/science.183.4124.534>, <https://doi.org/10.1038/35074122>, <https://doi.org/10.1038/ni1102-991>, <https://doi.org/10.1126/science.1203486> ;
  onco:tag "theory" ;
  onco:related <https://onco.cc/pathways/theories-of-cancer/>, <https://onco.cc/pathways/cancer-immunity-cycle/>, <https://onco.cc/terms/clonal-evolution-theory/>, <https://onco.cc/terms/microenvironment-inflammation-theory/>, <https://onco.cc/terms/hallmarks-synthesis/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/t-cell-exhaustion/>, <https://onco.cc/pathways/immune-desert-exclusion/>, <https://onco.cc/terms/avoiding-immune-destruction/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/tmb/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/til-therapy/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/lifileucel/> ;
  onco:pathways <https://onco.cc/pathways/cancer-immunity-cycle/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/t-cell-exhaustion/>, <https://onco.cc/pathways/immune-desert-exclusion/> ;
  onco:people <https://onco.cc/people/robert-schreiber/>, <https://onco.cc/people/james-allison/>, <https://onco.cc/people/tasuku-honjo/>, <https://onco.cc/people/drew-pardoll/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-schreiber-cancer-immunoediting-science-2011/>, <https://onco.cc/key-papers/paper-chen-mellman-cancer-immunity-cycle-immunity-2013/>, <https://onco.cc/key-papers/paper-leach-allison-ctla4-blockade-science-1996/>, <https://onco.cc/key-papers/paper-pardoll-immune-checkpoint-blockade-nrc-2012/>, <https://onco.cc/key-papers/paper-shankaran-nature/>, <https://onco.cc/key-papers/paper-dunn-nat-immunol/>, <https://onco.cc/key-papers/paper-stutman-science/>, <https://onco.cc/key-papers/paper-burnet-br-med-j/>, <https://onco.cc/key-papers/paper-burnet-prog-exp-tumor-res/> .